Predictive Validation and the Re-Analysis of Cost-Effectiveness: Do We Dare to Tread? Jonathan KarnonHossein Hajiali Afzali Editorial 22 August 2017 Pages: 1111 - 1112
Replicating Health Economic Models: Firm Foundations or a House of Cards? Inigo BermejoPaul TappendenJi-Hee Youn Current Opinion 26 July 2017 Pages: 1113 - 1121
A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection Hannah E. BurtonStephen A. MitchellMaureen Watt Systematic Review Open access 05 September 2017 Pages: 1123 - 1140
Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Iñigo BermejoMatt StevensonAdam Young Review Article 26 May 2017 Pages: 1141 - 1151
The Indonesian EQ-5D-5L Value Set Fredrick Dermawan PurbaJoke A. M. HunfeldJan J. V. Busschbach Original Research Article Open access 10 July 2017 Pages: 1153 - 1165
Mapping PROMIS Global Health Items to EuroQol (EQ-5D) Utility Scores Using Linear and Equipercentile Equating Nicolas R. ThompsonBrittany R. LapinIrene L. Katzan Original Research Article 14 July 2017 Pages: 1167 - 1176
Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer Laura McCullaghSusanne SchmitzCathal Walsh Original Research Article 02 August 2017 Pages: 1177 - 1185
Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?” Emma McManusTracey Sach Letter to the Editor 27 September 2017 Pages: 1187 - 1188
Response to ‘Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?”’ Inigo BermejoPaul TappendenJi-Hee Youn Letter to the Editor 27 September 2017 Pages: 1189 - 1190
